Columbia University Medical Center (CUMC) researchers have pinpointed the immune system mechanism that allows a kidney transplant to be accepted without lifelong immunosuppressive drugs, a significant step toward reducing or eliminating the need for costly and potentially toxic immunosuppressant drugs and improving long-term transplant success. The study is published in Science Translational Medicine.
Using a new technique for identifying and tracking specific cells, combined with advanced genetic sequencing, the researchers found a set of patient-specific T cells that react to the donor tissue, increasing in number in patients who reject the organ but gradually disappearing in patients who accept the organ without immunosuppression and are therefore considered to be immunologically ‘tolerant’ of their donors. The team state that this new technique provides a window into the fate of these T cells and has potential as an individualized biomarker for predicting and identifying rejection and tolerance in different types of transplant patients.
The researchers explain that when a patient receives a transplant, a unique population of lymphocytes, donor-reactive T cells, emerges to reject the foreign organ. Immunosuppressive medication is almost always required to prevent rejection of the donor tissue. Previously, it had not been possible in humans to identify these specific T cells because of their vast number and diversity. Furthermore, they are unpredictable and distinct for each transplant patient and donor.
Earlier studies suggested that a unique subset of T cells, called regulatory cells, play a role in initially inducing tolerance, but they seemed not to be involved in maintaining tolerance later on. Therefore, other explanations for long-term tolerance were needed. It was unclear whether the large number of donor-reactive T cells actually disappeared or were still present but inactive in long-term tolerant recipients. To learn more, the team devised a new technique for identifying and tracking these cells in the current study.
The researchers used the technique on blood samples taken from six kidney-transplant patients. Two of the patients had undergone conventional kidney transplants. The other four had received combined kidney and bone marrow transplantation (CKBMT) in a clinical trial and stopped taking immunosuppressants eight months after surgery. CKBMT, an experimental therapy, is known to produce an immune state that combines elements of both the recipient’s and donor’s immune systems. The team’s studies have shown that CKBMT induces tolerance of the transplanted organ without the need for long-term immunosuppressants. But the team didn’t understand the mechanism behind this tolerance.
In the current study, the researchers identified the donor-reactive T cells in each patient’s blood before transplant and repeated the test after transplant at three intervals (six, 12, and 18 months). Three of the four patients who underwent CKBMT showed a decrease in donor-reactive T cells from pre-transplant to post-transplant. All three tolerated the transplant. In the fourth CKBMT patient, the donor-reactive cells did not significantly decline over time, and the patient, unlike the others, rejected the donor kidney. The two patients who had the kidney transplant alone had an increase in donor-reactive T cell receptors.
The findings suggest that deletion of a specific set of donor-reactive T cells is a major mechanism governing tolerance of donor tissue. The current study also supports the approach of combining kidney transplants with bone marrow transplants, with its resultant elimination of donor-reactive T cells. This approach needs further study, but so far, all signs indicate that it could eliminate the need for lifelong immunosuppression.
The team summise that although immunosuppressant drugs have dramatically increased transplant success, they have notable drawbacks, including significant side effects and increased risk of cancer, opportunistic infections, hypertension, elevated cholesterol, and other conditions. On top of all that, the transplants often do not survive permanently because of the drugs and the constant attacks of the recipient’s immune system. The lab is currently planning a trial of CKBMT at CUMC.
biomarker, bone marrow transplant, gene sequencing, genetics, healthinnovations, immune response, immunology, immunosupression, kidney transplant, organ rejection, regulatory cell, surgery, transplant
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.